Amber Holly, LMFTA in Jackson, AL - Marriage & Family Therapist

Amber Holly, LMFTA is a Marriage & Family Therapist based in Jackson, Alabama. Amber Holly is licensed to practice in Alabama (license number A291) and her current practice location is 611 Commerce St, Jackson, Alabama. She can be reached at her office (for appointments etc.) via phone at (251) 320-4599.

NPI number for Amber Holly is 1043078850 and her current mailing address is 611 Commerce St, Jackson, Alabama. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1043078850.

Contact Information

	Amber Holly, LMFTA
	611 Commerce St, Jackson, AL 36545-3105
	(251) 320-4599
	Not Available

Healthcare Provider's Profile

Full Name	Amber Holly
Gender	Female
Speciality	Marriage & Family Therapist
Location	611 Commerce St, Jackson, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1043078850
Provider Enumeration Date: 03/07/2024
Last Update Date: 03/07/2024

Medical Identifiers

Medical identifiers for Amber Holly such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1043078850	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
106H00000X	Marriage & Family Therapist	A291 (Alabama)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Amber Holly is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Amber Holly, LMFTA 611 Commerce St, Jackson, AL 36545-3105 Ph: () -	Amber Holly, LMFTA 611 Commerce St, Jackson, AL 36545-3105 Ph: (251) 320-4599

News Archive

TGen researchers use RNAi-based screening to study Ewing's sarcoma

The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets, according to a scientific paper by the Translational Genomics Research Institute published this month in the journal Molecular Cancer.

Medicure to be delisted from TSX, announces intention to apply for alternative listing on TSX- V or NEX

Medicure Inc. announces that, following a review by the listings committee of the Toronto Stock Exchange (the "TSX"), the common shares of Medicure will be delisted from the TSX effective at the close of trading on February 26, 2010. While the Company will endeavor to meet the continued listing requirements of the TSX prior to the delisting date, the Company also intends to make application for listing of its common shares on the TSX Venture Exchange (the "TSX- V") or NEX to ensure continued and seamless trading liquidity for shareholders.

Review looks into conventional versus new treatment modalities in orthodontic pain management

Patients experience pain and discomfort during active orthodontic treatment with fixed appliances. It can vary from person to person and is influenced by certain factors such as age, gender, previous pain experiences, stress or anxiety, and type of appliance.

Researchers develop GI microbiome modulators to treat prediabetes and diabetes

In adults with prediabetes, a new drug that alters microbial populations and their environment in the gastrointestinal (GI) tract improves glucose tolerance-the body's response to consuming carbohydrates- after four weeks of treatment and without a change in diet.

New Lullaby Trust-funded study could prevent sudden, unexpected deaths of babies and children

An innovative new study funded by The Lullaby Trust is being launched, which could have profound implications for preventing the sudden and unexpected deaths of babies and children.

Amber Holly, LMFTA - Couples Therapy in Jackson, AL